医学
无容量
危险系数
内科学
头颈部癌
头颈部鳞状细胞癌
埃罗替尼
随机对照试验
临床终点
化疗
癌症
肿瘤科
外科
胃肠病学
免疫疗法
置信区间
表皮生长因子受体
作者
Vijay Patil,Vanita Noronha,Nandini Menon,Rahul Rai,Atanu Bhattacharjee,Ajay Singh,Kavita Nawale,Shweta Jogdhankar,Rupali Tambe,Sachin Dhumal,Riddhi Sawant,Mitali Alone,Devanshi Karla,Zoya Peelay,Shruti Pathak,Arun Balaji,Suman Kumar,Nilendu Purandare,Archi Agarwal,Ameya Puranik
摘要
To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
22336
Nole
v0id
Kao
didiwang
OK
ale
yjh123
Yuki
愉快的真
丰富语蕊
行走的荷尔蒙
嘻嘻哈哈
Oracle
XIAOATAIA
渡人舟
昏睡的蟠桃
MR_H
sagitar
皖公网安备34019202002308
